Lung Cancer Surgery Market Size, Share & Trends Analysis Report By Application, Regional Outlook, Competitive Strategies, And Segment Forecasts, 2019 To 2025

The global lung cancer surgery market is expected to gain a boost during the forecast period from increasing prevalence of lung cancer stemmed from factors such as rising air pollution levels coupled with an increasing number of cigarette smokers. According to estimates published by the American Association for Thoracic Surgery lung cancer was leading cause of cancer deaths in the U.S. in 2012. Increasing global incidence of lung cancer is a primary factor pushing growth of this market.

Lung cancer surgery market is studied with respect to two segments such as products and type of surgeries. Product segment of lung cancer surgery is further segmented into four types as surgical devices, endosurgical equipment and monitoring or visualizing equipment. Types of surgery segment is further subdivided in to robotic surgery, thoracotomy, video assisted surgery, percutaneous surgery and endobronchial surgery. Thoracotomy is extensively used surgical process for the treatment of lung cancer thereby attributing the largest market share in 2013. Thoracotomy also includes lobectomy or pneumonectomy which is used as lung cancer treatment. With the advent of technological advancements in the field of automation robotic surgeries are also gaining popularity and acceptance amongst healthcare professionals for surgical procedures. Robotic surgeries are minimally invasive in nature thereby providing comfort to the patients. However, comparatively expensive nature of robotic surgeries can act as a hurdle in emerging economies of Asia Pacific region such as India and China. 

On the basis of geography the market is segmented as North America, Europe, Asia Pacific and RoW. North American market with the virtue of higher prevalence rate of lung cancer coupled with advanced healthcare infrastructure supporting technologically advanced surgeries such as robotic surgery has emerged as the most mature market. Furthermore, Asia pacific is expected to be the most lucrative market owing to the rapidly developing healthcare infrastructure, increasing patient awareness levels, and acceptance of technologically developed robotic surgeries in Japan and emerging economies of India and China. 

The lung cancer surgery market has few prominent players investing majorly on R&D. Prominent players studied in this market include Accuray Inc., BSD Medical Corp., Covidien, Angiodynamics, Richard Wolf GMBH, Siemens Healthcare, Olympus Corp., Neomend Inc., Ethicon Endo surgery Inc., Teleflex, Trokamed GMBH and Scanlan International Inc.